Novartis's Sandoz division has struck a deal with Taiwan's EirGenix Inc to market a biosimilar version of Roche's Herceptin that is now in late-stage development to treat some cancer tumors.
from Latest News http://bit.ly/2ZJgkt3
Novartis's Sandoz strikes deal for biosimilar of Herceptin
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment